biotech / news / / Benzinga
The Foster City, California-based firm aims to enhance its oncology pipeline.
Gilead will acquire Tubulis for $3.15 billion upfront plus up to $1.85 billion in milestones.
KEY POINTS
- The Tubulis deal adds TUB-040, an antibody-drug conjugate for ovarian cancer, to Gilead's portfolio.
- Gilead is also acquiring Ouro Medicines for $1.675 billion upfront, expanding its inflammation pipeline.
- Gilead owns 11.5% of Arcellx's outstanding common stock, signaling deeper strategic interests.
COMPANIES
Summarized by Newsio from Benzinga. How we summarize →